As of Apr 25
| -1.30 / -6.53%|
The 1 analysts offering 12-month price forecasts for Cellular Biomedicine Group Inc have a median target of 32.00, with a high estimate of 32.00 and a low estimate of 32.00. The median estimate represents a +72.04% increase from the last price of 18.60.
The current consensus among 2 polled investment analysts is to Buy stock in Cellular Biomedicine Group Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.